Editors in Conversation is the official podcast of the American Society for Microbiology Journals. Editors in Conversation features discussions between ASM Jour...
2024 was a very active year on research in antimicrobial resistance, highlighted by an impactful and high level political declaration to combat antimicrobial resistance by the United Nations. In this episode, trainees from NIH-funded training program (T32) on antimicrobial resistance will help me discuss the most relevant research on the field in the year 2024. Welcome to editors in conversation! Topics discussed: The best papers of 2024 in gram-positive, gram-negative, mycobacterial and parasite resistance Guests: Nathalie Chen: University of Pittsburgh, Pittsburgh, PA Alex Kang: Houston Methodist Research Institute, Houston, TX Nathan Rabbe: University of Pittsburgh, Pittsburgh, PA Taylor Blackburn: Emory University, Atlanta, GA Jacon McPherson: University of Houston, Houston, TX. Harrison Lee, MD: Associate Chief of Epidemiology and Microbial Genomics, Professor of Medicine and Epidemiology, Director, Center for Genomic Epidemiology, Director, T32 AMR, U of Pittsburgh William Shafer, PhD: Professor, Department of Microbiology and Immunology, Emory University School of Medicine, Co-Director, Emory Antibiotic Resistance Center. Director T32 AMR, Emory University This episode is brought to you by the Antimicrobial Agents and Chemotherapy Journal. Visit asm.org/aac to browse issues and/or submit a manuscript. If you plan to publish in AAC, ASM Members get up to 50% off publishing fees. Visit asm.org/joinasm to sign up.
--------
54:12
Getting a Job in a Clinical Microbiology Lab
Looking for a dynamic and rewarding career? Learn what it means to be a Clinical Microbiology Laboratory Director and the necessary steps to get there. It’s a diverse job encompassing infectious diseases diagnostic testing, patient care, teaching, and research. This episode is geared for those who are interested in pursuing (or already have) a Ph.D. or M.D. Guests: Alexandra Bryson, Ph.D. Andrea Prinzi, Ph.D Links: Join ASM for up to 50% off the publication fees when you publish in JCM or any of the ASM journals. This episode of Editors in Conversation is brought to you by the Journal of Clinical Microbiology and hosted by JCM Editor in Chief, Alex McAdam and Dr. Elli Theel. JCM is available at https://jcm.asm.org and on https://twitter.com/JClinMicro. Visit journals.asm.org/journal/jcm to read articles and/or submit a manuscript. Follow JCM on Twitter/𝕏 via @JClinMicro
--------
17:30
The Global Antibiotic Research & Development Partnership (GARDP)
Lack of access to antibiotics including those with enhanced activity against multidrug-resistant organisms is a major barrier to combat antimicrobial resistance, particularly in the developing world. Furthermore, discovering and making available new antimicrobial agents against the most pressing antibiotic-resitant organisms is a challenge due to multiple barriers. The Global Antibiotic Research & Development Partnership (GARDP) accelerates the development and access of treatments for drug-resistant bacterial infections. Together with public, private and non-profit partners, GARDP works to preserve the power of antibiotics for generations to come. We discuss the important role that GARDP is playing in the worldwide fight against antimicrobial resistance. Topics discussed: GARDP function and role in the AMR field The strategies that GARDP is implementing to make new antibiotics available to all The future of antimicrobial research and development and the role of GARDP in this process. Guests: Jennifer Cohn MD MPH, Director, Global Access Global Antibiotic R&D Partnership (GARDP) Susana Ribeiro, MPH, Regional Head Latin America Global Antibiotic R&D Partnership (GARDP) This episode is brought to you by the Antimicrobial Agents and Chemotherapy Journal. Visit asm.org/aac to browse issues and/or submit a manuscript. If you plan to publish in AAC, ASM Members get up to 50% off publishing fees. Visit asm.org/joinasm to sign up.
--------
41:04
At-Home Collection and Testing for STIs
So you want validated, at-home, self-collected swabs for STI testing… Here's what you need to know! Sexually transmitted infection rates continue to climb across the US and while testing for these diseases is widely available, for the most part it requires the patient to go to a local clinic to collect and submit their sample for testing. But, is that really necessary, especially from a test accuracy perspective? Today’s guests answer that exact question. And I’m sure that many, if not all of us would agree that the ability for patients to collect samples outside of a clinical setting has numerous benefits, including what the authors refer to as pseudo-anonymity, increased comfort and ultimately increased access to testing, which would be of particular value for patients that may avoid clinical settings due to various different socioeconomic barriers. Watch this episode: https://youtu.be/40XCHpAFvqw Guests: Dr. Breland Hockman, who is a board certified clinical chemist and the Director of Clinical Affairs at LetsGetChecked.com Dr. Dina Greene, Clinical Professor at University of Washington, Department of Laboratory Medicine and Pathology and former Associate Lab Director at LetsGetChecked.com Links: Overcoming analytical and preanalytical challenges associated with extragenital home collected STI specimens Join ASM for up to 50% off the publication fees when you publish in JCM or any of the ASM journals. This episode of Editors in Conversation is brought to you by the Journal of Clinical Microbiology and hosted by JCM Editor in Chief, Alex McAdam and Dr. Elli Theel. JCM is available at https://jcm.asm.org and on https://twitter.com/JClinMicro. Visit journals.asm.org/journal/jcm to read articles and/or submit a manuscript. Follow JCM on Twitter/𝕏 via @JClinMicro
--------
34:37
High Level Meeting on AMR at the United Nations: A Debrief
The second High-Level Meeting on Antimicrobial Resistance (AMR) took place in New York on 26 September 2024 as the principal official, health-focused event during the UN General Assembly high-level week. The intergovernmental negotiations for the declaration were co-facilitated by Malta and Barbados. A political declaration for the meeting was produced highlighting the fact that AMR will cause even more global suffering, particularly in low- and middle-income countries. In this episode we will debrief and analyze the possible impact of these meetings and consequences for the future of AMR research and antimicrobial development. Topics discussed: The political implications of the UN declaration on AMR. Comment of the scientific and public health impact of the declaration Elaborate on future antimicrobial research and development Guests: John Rex, MD. Chief Medical Officer, F2G Ltd; Operating Partner, Advent Life Sciences Prabha Fernandes, PhD. Board Member of GARDP (Global Antibiotic Research and Development Partnership). Links: HLM on AMR at UNGA: The end of the beginning 29 April 2024: “R&D Implications: Global Burden of Disease is 28% Infectious!” 27 Sep 2024: “Without action, AMR costs go from $66b to $159b/yr by 2050” This episode is brought to you by the Antimicrobial Agents and Chemotherapy journal. Visit asm.org/aac to browse issues and/or submit a manuscript. If you plan to publish in AAC, ASM Members get up to 50% off publishing fees. Visit asm.org/joinasm to sign up.
Editors in Conversation is the official podcast of the American Society for Microbiology Journals. Editors in Conversation features discussions between ASM Journals Editors, researchers and clinicians working on the most cutting edge issues in the microbial sciences. Topics include laboratory diagnosis and clinical treatment of infectious diseases, antimicrobial resistance, epidemiology of infections, multidrug-resistant organisms, pharmacology of antimicrobial agents, susceptibility testing, and more.
The podcast is directed to microbiologists, infectious diseases clinicians, pharmacists and basic, clinical and translational researchers interested in the microbial sciences. A particular emphasis is on basic, epidemiological and pharmacological aspects of infectious diseases, including antimicrobial resistance and therapeutics.
México